Antithrombin iii

Full Generic Medicine Info
Dosage/Direction for Use

Thromboembolic disorders, Prophylaxis of thromboembolism associated with surgical and obstetric procedures
Adult: Dosing is individualised based on pre-therapy antithrombin (AT) level and clinical condition. Loading: Dose targeted to achieve 120% of normal AT level via infusion. Maintenance: Dose targeted to achieve 80-120% (approx 60% of initial loading dose) of normal AT level via infusion 24 hrly as needed.
Special Precautions
May carry a risk of transmitting infectious agents (e.g. viruses, Creutzfeldt Jakob disease agents). Pregnancy and lactation. Monitoring Parameters Monitor vital signs, cardiac and CNS status during and after therapy. Monitor AT level at baseline, 20 min (peak) and 12 hr post-infusion, and before the next infusion (trough). Measure peak and trough AT levels w/ each subsequent dose until desired levels achieved.
Adverse Reactions
Flushing, headache, dizziness, chest tightness, nausea, dysgeusia, chills, abdominal cramps, shortness of breath, lightheadedness, hives, fever; inj site oozing and haematoma. Rarely, allergic reactions.
ROUTE(S) : IV / Parenteral: B manufacturer specific
ROUTE(S) : IV / Parenteral: C manufacturer specific
Drug Interactions
May enhance anticoagulant effect and increase the risk of bleeding w/ heparin and other anticoagulants.
Antithrombin III, an α2-globulin, is the major inhibitor of in vivo coagulation. It inactivates thrombin, plasmin, and activated coagulation factors IXa, Xa, XIa, and XIIa, preventing the conversion of fibrinogen to fibrin, thereby inhibiting thrombus formation. Additionally, it is the cofactor through which heparin exerts in effect.
Distribution: Distributed into plasma (39%), extravascular space (49%), and vascular endothelial cells (11%).
Metabolism: Metabolised (<5%) to low molecular wt breakdown products.
Excretion: Via urine (as complex w/ thrombin or other proteinases). Terminal elimination half-life: Biphasic; 2.5-4.8 days.
Intravenous: Store below 25°C. Do not freeze.
ATC Classification
B01AB02 - antithrombin III ; Belongs to the class of heparin group. Used in the treatment of thrombosis.
Disclaimer: This information is independently developed by CIMS based on antithrombin iii from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in